Juvana M. Andrade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juvana M. Andrade has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina V. S. C. de Araujo
Universidade de São Paulo
1 shared publication André Báfica
Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis , Santa Catarina
1 shared publication- Bruno de Paula Oliveira Santos
Department of Chemistry “Ugo Schiff” and Magnetic Resonance Center (CERM), University of Florence, via Luigi Sacconi, 6, 50019 Sesto Fiorentino (FI), Italy
1 shared publication - Daniel Augusto G.B. Mendes
Laboratory of Immunobiology, Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina , Florianópolis
1 shared publication Daniel S. Mansur
Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis , Santa Catarina
1 shared publication- E. Jane Homan
IoGenetics LLC, 301 South Bedford Street, Ste.1, Madison, WI, 53703, USA
1 shared publication
Latest Publications
- Open Access
- 26 April 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (12) , 1925-1937
Recombinant Bacillus Calmette–Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge
COVID-19 has accounted for more than 6 million deaths worldwide. Bacillus Calmette–Guérin (BCG), the existing tuberculosis vaccine, is known to induce heterologous effects over other infections due to trained immunity and has been proposed to be a potential strategy against SARS-CoV-2 infection. In this report, we constructed a recombinant BCG (rBCG) expressing domains of the SARS-CoV-2 nucleocapsid and spike proteins (termed rBCG-ChD6), recognized as major candidates for vaccine development. We investigated whether rBCG-ChD6 immunization followed by a boost with the recombinant nucleocapsid and spike chimera (rChimera), together with alum, provided protection against SARS-CoV-2 infection in K18-hACE2 mice. A single dose of rBCG-ChD6 boosted with rChimera associated with alum elicited the highest anti-Chimera total IgG and IgG2c Ab titers with neutralizing activity against SARS-CoV-2 Wuhan strain when compared with control groups. Importantly, following SARS-CoV-2 challenge, this vaccination regimen induced IFN-γ and IL-6 production in spleen cells and reduced viral load in the lungs. In addition, no viable virus was detected in mice immunized with rBCG-ChD6 boosted with rChimera, which was associated with decreased lung pathology when compared with BCG WT-rChimera/alum or rChimera/alum control groups. Overall, our study demonstrates the potential of a prime-boost immunization system based on an rBCG expressing a chimeric protein derived from SARS-CoV-2 to protect mice against viral challenge.
- 26 April 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (12) , 1925-1937
Open AccessRecombinant Bacillus Calmette–Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge
COVID-19 has accounted for more than 6 million deaths worldwide. Bacillus Calmette–Guérin (BCG), the existing tuberculosis vaccine, is known to induce heterologous effects over other infections due to trained immunity and has been proposed to be a potential strategy against SARS-CoV-2 infection. In this report, we constructed a recombinant BCG (rBCG) expressing domains of the SARS-CoV-2 nucleocapsid and spike proteins (termed rBCG-ChD6), recognized as major candidates for vaccine development. We investigated whether rBCG-ChD6 immunization followed by a boost with the recombinant nucleocapsid and spike chimera (rChimera), together with alum, provided protection against SARS-CoV-2 infection in K18-hACE2 mice. A single dose of rBCG-ChD6 boosted with rChimera associated with alum elicited the highest anti-Chimera total IgG and IgG2c Ab titers with neutralizing activity against SARS-CoV-2 Wuhan strain when compared with control groups. Importantly, following SARS-CoV-2 challenge, this vaccination regimen induced IFN-γ and IL-6 production in spleen cells and reduced viral load in the lungs. In addition, no viable virus was detected in mice immunized with rBCG-ChD6 boosted with rChimera, which was associated with decreased lung pathology when compared with BCG WT-rChimera/alum or rChimera/alum control groups. Overall, our study demonstrates the potential of a prime-boost immunization system based on an rBCG expressing a chimeric protein derived from SARS-CoV-2 to protect mice against viral challenge.